Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer

NCT00523315 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00523315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00523315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 31, 2007
Completion date
April 30, 2011
Enrollment
862 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer